TrialRMD open2026

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

Ioannis Parodis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.